Health and Healthcare

BioMarin : BMRN

All BioMarin Articles

169 Articles

Lee Jackson | Sep 25, 2015 at 9:50 AM EDT

3 Top Jefferies Biotech Picks to Buy on Recent Sector Weakness

In a recent research report, Jefferies highlighted three top biotech companies that are very tempting buys now.

Lee Jackson | Aug 6, 2015 at 9:15 AM EDT

Cowen Raises Price Targets on Focus Call Stocks to Buy

Now is the time to really review portfolios and replace momentum winners with earnings growth leaders. The Cowen Focus Call…

Lee Jackson | Aug 3, 2015 at 10:40 AM EDT

3 Biotech Stocks to Buy With Huge Catalysts Coming Soon

SunTrust Robinson Humphrey handicaps some of the upcoming events for stocks in the firm's coverage universe that have potential market-moving…

Lee Jackson | Jul 20, 2015 at 8:50 AM EDT

4 Large Cap Biotech Stocks to Buy Before Earnings

A new research report from Cowen focuses on the top biotech stocks to buy before second-quarter earnings are reported.

Jon C. Ogg | Jun 19, 2015 at 8:50 AM EDT

Top Analyst Upgrades and Downgrades: BioMarin, BP, Micron, Vonage, Finisar, ConEd, Red Hat and More

Friday's top analyst upgrades, downgrades and initiations include BioMarin Pharmaceuticals, BP, Micron Technology, Vonage, Finisar, Consolidated Edison and Red Hat.

Jon C. Ogg | Jun 18, 2015 at 1:40 PM EDT

3 Drivers Supporting BioMarin

BioMarin Pharmaceutical has three key drivers helping out its shares on Thursday: drug news, analyst support, record high Nasdaq.

Lee Jackson | May 27, 2015 at 8:20 AM EDT

Analyst Has 4 Top US Growth Stock Calls for This Week

A recent research piece from the analysts at Jefferies presents the firm's four top growth stock calls for this holiday-shortened…

Lee Jackson | May 7, 2015 at 8:30 AM EDT

Why These 4 Biotech Stocks Could Be the Next Buyout Targets

A new research note from SunTrust Robinson Humphrey mentions four stocks that they think could possibly get swept up in…

Lee Jackson | May 6, 2015 at 10:00 AM EDT

Huge Buyout Highlights 4 Deutsche Bank Biotech Focus Stocks

In a new report, Deutsche Bank acknowledges that while the industry has shown recent weakness, now may be just the…

Lee Jackson | Mar 27, 2015 at 8:35 AM EDT

RBC Has 4 Biotech Stocks to Buy After Massive Pullback

In a new report from RBC, while they think the selling and profit taking in biotechs could go on, they…

Chris Lange | Mar 18, 2015 at 2:10 PM EDT

How the Weaker Euro Is Impacting Biotech Earnings

Wells Fargo released a report Wednesday that considers the future of major biotech companies in relation to the weak euro.

Lee Jackson | Mar 6, 2015 at 8:20 AM EST

The Next 3 Likely Biotech Buyout Candidates

Here are three biotech stocks that a SunTrust analyst feels could be buyout candidates, in the wake of the Pharmacyclics…

Lee Jackson | Feb 27, 2015 at 9:30 AM EST

Cowen Raises Price Targets on Top Momentum Stocks

These four companies are not only delivering the goods when it comes to earnings and growth prospects, but leading their…

Chris Lange | Feb 17, 2015 at 3:01 PM EST

Why 1 Analyst Sees Over 50% Upside in Sarepta

Sarepta Therapeutics received a favorable rating from Merrill Lynch, and as a result the stock soared in Tuesday's trading session.

Chris Lange | Feb 9, 2015 at 2:43 PM EST

Analyst Sees BioMarin Up Another 25%

BioMarin Pharmaceutical received a favorable analyst call from Merrill Lynch in Monday.

1 … 6 7 8 9 10 … 12

BioMarin : BMRN

All BioMarin Articles

3 Top Jefferies Biotech Picks to Buy on Recent Sector Weakness

Cowen Raises Price Targets on Focus Call Stocks to Buy

3 Biotech Stocks to Buy With Huge Catalysts Coming Soon

4 Large Cap Biotech Stocks to Buy Before Earnings

Top Analyst Upgrades and Downgrades: BioMarin, BP, Micron, Vonage, Finisar, ConEd, Red Hat and More

3 Drivers Supporting BioMarin

Analyst Has 4 Top US Growth Stock Calls for This Week

Why These 4 Biotech Stocks Could Be the Next Buyout Targets

Huge Buyout Highlights 4 Deutsche Bank Biotech Focus Stocks

RBC Has 4 Biotech Stocks to Buy After Massive Pullback

How the Weaker Euro Is Impacting Biotech Earnings

The Next 3 Likely Biotech Buyout Candidates

Cowen Raises Price Targets on Top Momentum Stocks

Why 1 Analyst Sees Over 50% Upside in Sarepta

Analyst Sees BioMarin Up Another 25%

UFO ETF Faces a Critical Test: Can Pre-Profit Space Stocks Deliver on $1.85B Backlog

Concentration Risk High as Top Two Stocks Steer U.S. Communication Services ETF Performance

Amazon and Tesla Drive One-Third of FDIS as U.S. Spending Surges Despite Recession-Level Sentiment

Fed’s Rate Freeze Could Sting for Social Security Recipients

'Convert $100,000 a Year to Get Them to the Top of the 22%': The Roth Plan for a Couple With $2.3M in 401(k)s

UFO ETF Faces a Critical Test: Can Pre-Profit Space Stocks Deliver on $1.85B Backlog

Concentration Risk High as Top Two Stocks Steer U.S. Communication Services ETF Performance

BioMarin : BMRN

All BioMarin Articles

3 Top Jefferies Biotech Picks to Buy on Recent Sector Weakness

Cowen Raises Price Targets on Focus Call Stocks to Buy

3 Biotech Stocks to Buy With Huge Catalysts Coming Soon

4 Large Cap Biotech Stocks to Buy Before Earnings

Top Analyst Upgrades and Downgrades: BioMarin, BP, Micron, Vonage, Finisar, ConEd, Red Hat and More

3 Drivers Supporting BioMarin

Analyst Has 4 Top US Growth Stock Calls for This Week

Why These 4 Biotech Stocks Could Be the Next Buyout Targets

Huge Buyout Highlights 4 Deutsche Bank Biotech Focus Stocks

RBC Has 4 Biotech Stocks to Buy After Massive Pullback

How the Weaker Euro Is Impacting Biotech Earnings

The Next 3 Likely Biotech Buyout Candidates

Cowen Raises Price Targets on Top Momentum Stocks

Why 1 Analyst Sees Over 50% Upside in Sarepta

Analyst Sees BioMarin Up Another 25%

UFO ETF Faces a Critical Test: Can Pre-Profit Space Stocks Deliver on $1.85B Backlog

Concentration Risk High as Top Two Stocks Steer U.S. Communication Services ETF Performance

Amazon and Tesla Drive One-Third of FDIS as U.S. Spending Surges Despite Recession-Level Sentiment

Featured Reads

Fed’s Rate Freeze Could Sting for Social Security Recipients

'Convert $100,000 a Year to Get Them to the Top of the 22%': The Roth Plan for a Couple With $2.3M in 401(k)s